Finanzas de Edesa Biotech Inc (EDSA)EDSAEdesa Biotech Inc

Edesa Biotech Inc (EDSA) generates its revenue primarily from KLH Operation, which accounts for 100.0% of total sales, equivalent to $102.58K. Understanding this concentration is critical for investors evaluating how EDSA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Edesa Biotech Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -531.32%, provide a clear picture of how effectively EDSA converts its operational activities into shareholder value.

In the context of the broader market, EDSA competes directly with industry leaders such as LITS and NNVC. With a market capitalization of $20.92M, it holds a significant position in the sector. When comparing efficiency, EDSA's gross margin of N/A stands against LITS's N/A and NNVC's N/A. Such benchmarking helps identify whether Edesa Biotech Inc is trading at a premium or discount relative to its financial performance.

Edesa Biotech has not generated significant revenue, reporting only $50,918 in Q2 2026, while suffering a net loss of $5.4 million for the same quarter. The company has a forward P/E ratio of 0.1785, which suggests it is trading at a very low valuation relative to its expected earnings, but this also reflects uncertainty about future profitability.